CRMD Stock Analysis: Buy, Sell, or Hold?
CRMD - CorMedix Inc.
$7.32
0.08 (1.10%)
▲
5d:
+3.39%
30d:
+14.37%
90d:
-4.06%
BUY
MODERATE Confidence
Analysis Updated: Apr 13, 2026 12:00 AM ET
Earnings: May 05, 2026
21d
Smart Money Distribution
CRMD is up 4.8% this week, but smart money is buying puts. Top strike: $6 2026-05-15 with 4,543 OI. Put ratio: 69% View Scanner →
Strength: 4.4/10
Get Alerted When CRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRMD shows positive signals but monitor for confirmation. Market pricing in 16.2% growth. Moderate conviction.
💡 BUY OPPORTUNITY: CRMD shows positive signals but monitor for confirmation. Market pricing in 16.2% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$4.06
Based on -2.7% avg growth
INTRINSIC VALUE TODAY
$2.52
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CRMD is currently trading at $7.32, which is considered extended relative to its 30-day fair value range of $6.37 to $7.05. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.0) compared to its historical average (6.4). At these levels, the market is pricing in 16.2% annual earnings growth.
Technical Outlook: Technically, CRMD is in a strong downtrend. The price is approaching resistance at $7.42. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRMD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.57 (+99.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRMD is in a strong downtrend. The price is approaching resistance at $7.42. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRMD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.57 (+99.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$6.37 -
$7.05
Company Quality Score
56/100
(HOLD)
Options IV Signal
40th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
66.2%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 40th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 99.1% below Wall St target ($14.57)
- BULLISH: Expecting earnings turnaround to 16.2% growth with 312.1% revenue growth
Fair Price Analysis
30-Day Fair Range
$6.37 -
$7.05
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$0.91
(12.4%)
Support & Resistance Levels
Support Level
$6.56
Resistance Level
$7.42
Current Trend
Strong Downtrend
Technical data as of
Apr 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.03
Wall Street Target
$14.57
(+99.1%)
Revenue Growth (YoY)
312.1%
Earnings Growth (YoY)
-28.3%
Profit Margin
52.3%
Valuation Premium vs History
+16.2% premium
PE vs Historical
10.0 vs 6.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+16.2%
(market-implied from PE analysis)
1-Year Target
$8.51
(+16%)
2-Year Target
$9.88
(+35%)
3-Year Target
$11.48
(+57%)
3-Yr Target (if PE normalizes)
(PE: 10→6)
PE COMPRESSION
$7.33
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: -9.3%)
$11.20
(+53%)
Base:
(SPY PE: 10.0, Growth: -9.3%)
$5.46
(-25%)
Bear:
(PE: 6.4, Growth: -9.3%)
$3.48
(-52%)
📈
Valuation based on Current Earnings
Trailing PE: 3.55 | Current EPS (TTM): $2.04
Bull Case
$3.98
(-46%)
Analyst growth -50.0%, PE expands to 3.9
Base Case
$3.62
(-51%)
Market implied -50.0%, PE stable at 3.6
Bear Case
$4.92
(-33%)
Severe decline -20.0%, PE contracts to 3.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 13, 2026 6:45 PM ET
Data refreshes hourly during market hours. Next update: 7:45 PM
Data refreshes hourly during market hours. Next update: 7:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRMD showing a specific setup today?
Insider Activity (6 Months)
1
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Alan W Dunton
SELL
20000 shares
2025-12-30
Joseph Todisco
SELL
30000 shares
2025-12-18
Steven W Lefkowitz
SELL
40000 shares
2025-12-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 49 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 57 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 59 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 62 BUY |
Advanced CRMD Option Strategies
Professional options setups generated by AI based on today's CRMD price and gamma walls.
